个人中心 - 老虎社区

TradeLegend

IP属地：未知

帖子 · 134帖子 · 134
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- TradeLegendTradeLegend
  ·2021-12-21
  🤑
  非常抱歉，此主贴已删除
  1,375 2
  4
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-20
  🤑
  Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
  The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5
  Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
  1,147 3
  6
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-18
  🤑
  DaVita authorizes additional $2B share repurchase
  DaVita Board of Directors increased the authorization under the existing share repurchase program b
  DaVita authorizes additional $2B share repurchase
  906 2
  5
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-17
  🤑
  Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain
  New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.
  Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain
  1,415 1
  3
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-16
  🤑
  All the doves at the Fed have become hawks
  The U.S. central bank charts a completely new course to attack inflation rather than continue to wai
  All the doves at the Fed have become hawks
  1,286 3
  6
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-15
  🤑
  非常抱歉，此主贴已删除
  1,605 1
  4
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-14
  🤑
  非常抱歉，此主贴已删除
  1,188 1
  3
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-13
  🤑
  Stock Futures Edge Up After S&P 500 Hits Record
  U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank dec
  Stock Futures Edge Up After S&P 500 Hits Record
  1,563 2
  2
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-13
  🤑
  非常抱歉，此主贴已删除
  1,201 3
  7
  分享
  举报
- TradeLegendTradeLegend
  ·2021-12-11
  🤑
  Tesla stops taking Model S and Model X orders outside North America
  Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outs
  Tesla stops taking Model S and Model X orders outside North America
  1,351 1
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3565930395680990","uuid":"3565930395680990","gmtCreate":1602836610802,"gmtModify":1706620606114,"name":"TradeLegend","pinyin":"tradelegend","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":7,"tweetSize":134,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":693599866,"gmtCreate":1640047130884,"gmtModify":1640047131033,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693599866","repostId":"1184187118","repostType":4,"isVote":1,"tweetType":1,"viewCount":1375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693069194,"gmtCreate":1639930012033,"gmtModify":1639930012195,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/693069194","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohunote.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","CERN":"美国塞纳","ARNA":"阿里那"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699270807,"gmtCreate":1639824405751,"gmtModify":1639824405859,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699270807","repostId":"1189235922","repostType":4,"repost":{"id":"1189235922","kind":"news","pubTimestamp":1639809269,"share":"https://www.laohunote.com/m/news/1189235922?lang=&edition=full","pubTime":"2021-12-18 14:34","market":"us","language":"en","title":"DaVita authorizes additional $2B share repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1189235922","media":"Seeking Alpha","summary":"DaVita  Board of Directors increased the authorization under the existing share repurchase program b","content":"<p><a href=\"https://laohu8.com/S/DVA\">DaVita </a> Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.</p>\n<p>The amount of shares authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on December 10, 2020 .</p>\n<p>Some bearish commentary and rating on the stock by SA contributor who writes: 'The company appears to be overvalued, and there are several challenges facing the company in the future.'</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DaVita authorizes additional $2B share repurchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaVita authorizes additional $2B share repurchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 14:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DaVita  Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.\nThe amount of shares authorized to be repurchased under ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVA":"达维塔保健"},"source_url":"https://seekingalpha.com/news/3781473-davita-authorizes-additional-2b-share-repurchase","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189235922","content_text":"DaVita  Board of Directors increased the authorization under the existing share repurchase program by $2B in additional repurchasing authority.\nThe amount of shares authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on December 10, 2020 .\nSome bearish commentary and rating on the stock by SA contributor who writes: 'The company appears to be overvalued, and there are several challenges facing the company in the future.'","news_type":1},"isVote":1,"tweetType":1,"viewCount":906,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690450573,"gmtCreate":1639703743619,"gmtModify":1639703743744,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690450573","repostId":"2192194909","repostType":4,"repost":{"id":"2192194909","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1639701314,"share":"https://www.laohunote.com/m/news/2192194909?lang=&edition=full","pubTime":"2021-12-17 08:35","market":"us","language":"en","title":"Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2192194909","media":"Investors","summary":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.","content":"<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.</p>\n<p>Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p>\n<p>The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p>\n<p>\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p>\n<h2>ADGI Stock Continues Its Wild Ride</h2>\n<p>Antibody drugs have taken a wild ride on the omicron train.</p>\n<p>Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p>\n<p>But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p>\n<p>\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p>\n<p>The news on Thursday resulted in another flip for ADGI stock, however.</p>\n<p>The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p>\n<h2>Other Antibodies Target Omicron</h2>\n<p>Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p>\n<p>AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p>\n<p>Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p>\n<p>It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-12-17 08:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.</p>\n<p>Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p>\n<p>The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p>\n<p>\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p>\n<h2>ADGI Stock Continues Its Wild Ride</h2>\n<p>Antibody drugs have taken a wild ride on the omicron train.</p>\n<p>Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p>\n<p>But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p>\n<p>\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p>\n<p>The news on Thursday resulted in another flip for ADGI stock, however.</p>\n<p>The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p>\n<h2>Other Antibodies Target Omicron</h2>\n<p>Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p>\n<p>AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p>\n<p>Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p>\n<p>It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192194909","content_text":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant — and ADGI stock soared on Thursday.\nTwo studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.\nThe news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with Vir Biotechnology and GlaxoSmithKline. Also this week, the duo said their antibody could effectively target omicron.\n\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.\nADGI Stock Continues Its Wild Ride\nAntibody drugs have taken a wild ride on the omicron train.\nVaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.\nBut omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.\n\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.\nThe news on Thursday resulted in another flip for ADGI stock, however.\nThe laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.\nOther Antibodies Target Omicron\nSimilarly, on Thursday, AstraZeneca said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.\nAstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.\nMeanwhile, Regeneron Pharmaceuticals stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.\nIt's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690059971,"gmtCreate":1639615627130,"gmtModify":1639615627236,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690059971","repostId":"1172070133","repostType":4,"repost":{"id":"1172070133","kind":"news","pubTimestamp":1639621250,"share":"https://www.laohunote.com/m/news/1172070133?lang=&edition=full","pubTime":"2021-12-16 10:20","market":"us","language":"en","title":"All the doves at the Fed have become hawks","url":"https://stock-news.laohu8.com/highlight/detail?id=1172070133","media":"MarketWatch","summary":"The U.S. central bank charts a completely new course to attack inflation rather than continue to wai","content":"<p>The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out</p>\n<p><img src=\"https://static.tigerbbs.com/ba1b24817095f66e1cbf69b3dd7a4ad8\" tg-width=\"700\" tg-height=\"399\" referrerpolicy=\"no-referrer\"></p>\n<p>The big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying bonds to stimulate the economy&nbsp;or that it’s now signaling three increases in its benchmark lending rate in 2022. Those short-term policy decisions had been well-telegraphed by Fed officials over the past month.</p>\n<p>No, the big surprise is that the gargantuan, change-averse Fed has turned 180 degrees in its view of inflation.</p>\n<p>The Fed’s statement&nbsp;Wednesday and the accompanying materials show that the doves — the policy makers who generally believe that the risk of inflation is overblown — have completely surrendered. Everyone’s a hawk now. There are no doves at the Fed anymore.</p>\n<p>Fed monetary-policy makers unanimously agree that fighting inflation is their No. 1 job. They may disagree on the tactics or the timing, but not on the strategy of vanquishing inflation soon. The Fed is on a war footing, and inflation is the enemy.</p>\n<p>For 30 years, the doves had been right: Inflation wasn’t the biggest threat to the economy; unemployment was. The doves fought an ultimately successful battle to force the Federal Reserve to consider the very real costs that unemployment forces upon society and the many individuals whom the economy was leaving behind.</p>\n<p>But now effects of the coronavirus pandemic have forced even the doves to accept that inflation is a bigger threat than unemployment. That’s a huge change in an institution that doesn’t like change.</p>\n<p>How do we know the doves have metamorphosed into hawks? Look at the dot plot, a chart the Fed releases every three months that shows the anonymous individual forecasts of each monetary-policy maker for the level of the federal funds rate at the ends of the next several years.</p>\n<p>Most analysts correctly focus on the median forecast for the coming year, but I’d like to redirect your attention briefly to the medium-term forecasts of the outliers, the most hawkish and dovish members of the Fed, to show how much the battlefield inside the Fed has changed since that horrendous consumer-price-index reading of Nov. 10. That report changed everything at the Fed.</p>\n<p><img src=\"https://static.tigerbbs.com/fc738ce106c9173e3b5b93bf435f87f7\" tg-width=\"700\" tg-height=\"644\" referrerpolicy=\"no-referrer\"></p>\n<p>In the latest forecasts released Wednesday, the most hawkish members raised their medium-term forecasts modestly from 1.63% to 2.13% at the end of 2023, and from 2.63% to 3.13% at the end of 2024. The five most hawkish members now think the Fed will have to push the fed funds rate above its assumed long-run equilibrium of 2.5%.</p>\n<p>But the doves completely tore up their previous forecasts. The five most dovish members were forecasting between zero and two rate hikes by the end of 2023, but now they expect four or five. By the end of 2024, they had been forecasting between two and four rate hikes; now they expect seven.</p>\n<p>Clearly, even the most dovish Fed officials now believe&nbsp;the fed funds rate must go up a lot to vanquish inflation. Before, they thought inflation would come down all by itself.</p>\n<p>This means that inflation no longer gets the benefit of the doubt. It’s been proven guilty, and even the doves will prosecute the war until victory is won. For the inflation doves at the Fed, Nov. 10, 2021, was bit of like Dec. 7, 1941: Time to go to war.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>All the doves at the Fed have become hawks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAll the doves at the Fed have become hawks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out\n\nThe big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying ...</p>\n\n<a href=\"https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/all-the-doves-at-the-fed-have-become-hawks-11639613760?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172070133","content_text":"The U.S. central bank charts a completely new course to attack inflation rather than continue to wait it out\n\nThe big news from the Federal Reserve’s meeting Wednesday wasn’t that it’ll stop buying bonds to stimulate the economy or that it’s now signaling three increases in its benchmark lending rate in 2022. Those short-term policy decisions had been well-telegraphed by Fed officials over the past month.\nNo, the big surprise is that the gargantuan, change-averse Fed has turned 180 degrees in its view of inflation.\nThe Fed’s statement Wednesday and the accompanying materials show that the doves — the policy makers who generally believe that the risk of inflation is overblown — have completely surrendered. Everyone’s a hawk now. There are no doves at the Fed anymore.\nFed monetary-policy makers unanimously agree that fighting inflation is their No. 1 job. They may disagree on the tactics or the timing, but not on the strategy of vanquishing inflation soon. The Fed is on a war footing, and inflation is the enemy.\nFor 30 years, the doves had been right: Inflation wasn’t the biggest threat to the economy; unemployment was. The doves fought an ultimately successful battle to force the Federal Reserve to consider the very real costs that unemployment forces upon society and the many individuals whom the economy was leaving behind.\nBut now effects of the coronavirus pandemic have forced even the doves to accept that inflation is a bigger threat than unemployment. That’s a huge change in an institution that doesn’t like change.\nHow do we know the doves have metamorphosed into hawks? Look at the dot plot, a chart the Fed releases every three months that shows the anonymous individual forecasts of each monetary-policy maker for the level of the federal funds rate at the ends of the next several years.\nMost analysts correctly focus on the median forecast for the coming year, but I’d like to redirect your attention briefly to the medium-term forecasts of the outliers, the most hawkish and dovish members of the Fed, to show how much the battlefield inside the Fed has changed since that horrendous consumer-price-index reading of Nov. 10. That report changed everything at the Fed.\n\nIn the latest forecasts released Wednesday, the most hawkish members raised their medium-term forecasts modestly from 1.63% to 2.13% at the end of 2023, and from 2.63% to 3.13% at the end of 2024. The five most hawkish members now think the Fed will have to push the fed funds rate above its assumed long-run equilibrium of 2.5%.\nBut the doves completely tore up their previous forecasts. The five most dovish members were forecasting between zero and two rate hikes by the end of 2023, but now they expect four or five. By the end of 2024, they had been forecasting between two and four rate hikes; now they expect seven.\nClearly, even the most dovish Fed officials now believe the fed funds rate must go up a lot to vanquish inflation. Before, they thought inflation would come down all by itself.\nThis means that inflation no longer gets the benefit of the doubt. It’s been proven guilty, and even the doves will prosecute the war until victory is won. For the inflation doves at the Fed, Nov. 10, 2021, was bit of like Dec. 7, 1941: Time to go to war.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607695836,"gmtCreate":1639530829485,"gmtModify":1639530829588,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607695836","repostId":"1129773083","repostType":4,"isVote":1,"tweetType":1,"viewCount":1605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604472686,"gmtCreate":1639442680885,"gmtModify":1639442680992,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604472686","repostId":"2191811539","repostType":4,"isVote":1,"tweetType":1,"viewCount":1188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604675566,"gmtCreate":1639395534696,"gmtModify":1639395534808,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604675566","repostId":"1131710846","repostType":4,"repost":{"id":"1131710846","kind":"news","pubTimestamp":1639393441,"share":"https://www.laohunote.com/m/news/1131710846?lang=&edition=full","pubTime":"2021-12-13 19:04","market":"fut","language":"en","title":"Stock Futures Edge Up After S&P 500 Hits Record","url":"https://stock-news.laohu8.com/highlight/detail?id=1131710846","media":"WSJ","summary":"U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank dec","content":"<p>U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.</p>\n<p>Futures for the S&amp;P 500 rose 0.2% Monday, after the benchmark gauge closed last week at its67th record high of 2021. Contracts for the Dow Jones Industrial Average, which sits just shy of an all-time high, also ticked up 0.2%, as did futures for the technology-heavy Nasdaq-100.</p>\n<p>In the bond market, the yield on benchmark 10-year Treasury notes ticked up to 1.492% Monday from 1.487% Friday. Yields move in the opposite direction to bond prices.</p>\n<p>Investors are sitting tight ahead of a monetary-policy decision by the Federal Reserve and announcements from the Bank of England, European Central Bank and&nbsp;Bank of Japan&nbsp;later in the week. The Fed is expected to accelerate the pace at which it is paring its bond-buying program and to signal that it will raise interest rates next year to tap the brakes on inflation. Data published Friday showed consumer prices increased in November at the&nbsp;fastest annual rate since 1982.</p>\n<p>Gregory Perdon, co-chief investment officer at&nbsp;Arbuthnot Latham,said he expects stocks to keep rising even as the Fed tightens monetary policy.</p>\n<p>“The classic textbook would be rates up, stocks down,” Mr. Perdon said. “The reality is there’s so much liquidity out there, there’s so much demand to get a return on assets that ultimately we’re going to have to have a much…more aggressive tightening to knock stocks.”</p>\n<p>Commodity prices rose. Brent-crude futures, the benchmark in international energy markets, ticked up 0.5% to $75.53 a barrel. Prices snapped a six-week losing streak Friday, recovering some ground shed when the Omicron variant threatened to hit oil demand.</p>\n<p>European natural-gas prices jumped more than 8% Monday. Supplies of gas, a key heating and power-generation fuel in Europe, are well below their recent average for the time of year, raising concerns stockpiles will run low as cold weather lifts demand. U.S. natural-gas futures rose 1.9% to $4 per million British thermal units.</p>\n<p>Turkey’s lira slumped 4% to trade at 14.46 to the dollar ahead of an expected rate cut by the central bank on Thursday. The Central Bank of the Republic of Turkey has bowed to pressure from President Recep Tayyip Erdogan to lower borrowing costs this year in the face of rapid inflation, hitting the currency hard.</p>\n<p>Overseas stock markets were mixed. The Stoxx Europe 600 edged up 0.1%, led higher by shares of basic-resources, auto and oil-and-gas companies. Among individual movers,Vifor Pharmajumped more than 15% after the Swiss pharmaceutical firm said it was in talks to be bought by Australia’s CSL.</p>\n<p>Japan’s Nikkei 225 rose 0.7%, the Shanghai Composite Index added 0.4% and Hong Kong’s Hang Seng slipped 0.2%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Futures Edge Up After S&P 500 Hits Record</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Futures Edge Up After S&P 500 Hits Record\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 19:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/global-stock-markets-dow-update-12-13-2021-11639384564?mod=hp_lead_pos1><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.\nFutures for the S&P 500 rose 0.2% Monday, after the benchmark gauge ...</p>\n\n<a href=\"https://www.wsj.com/articles/global-stock-markets-dow-update-12-13-2021-11639384564?mod=hp_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.wsj.com/articles/global-stock-markets-dow-update-12-13-2021-11639384564?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131710846","content_text":"U.S. stock futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.\nFutures for the S&P 500 rose 0.2% Monday, after the benchmark gauge closed last week at its67th record high of 2021. Contracts for the Dow Jones Industrial Average, which sits just shy of an all-time high, also ticked up 0.2%, as did futures for the technology-heavy Nasdaq-100.\nIn the bond market, the yield on benchmark 10-year Treasury notes ticked up to 1.492% Monday from 1.487% Friday. Yields move in the opposite direction to bond prices.\nInvestors are sitting tight ahead of a monetary-policy decision by the Federal Reserve and announcements from the Bank of England, European Central Bank and Bank of Japan later in the week. The Fed is expected to accelerate the pace at which it is paring its bond-buying program and to signal that it will raise interest rates next year to tap the brakes on inflation. Data published Friday showed consumer prices increased in November at the fastest annual rate since 1982.\nGregory Perdon, co-chief investment officer at Arbuthnot Latham,said he expects stocks to keep rising even as the Fed tightens monetary policy.\n“The classic textbook would be rates up, stocks down,” Mr. Perdon said. “The reality is there’s so much liquidity out there, there’s so much demand to get a return on assets that ultimately we’re going to have to have a much…more aggressive tightening to knock stocks.”\nCommodity prices rose. Brent-crude futures, the benchmark in international energy markets, ticked up 0.5% to $75.53 a barrel. Prices snapped a six-week losing streak Friday, recovering some ground shed when the Omicron variant threatened to hit oil demand.\nEuropean natural-gas prices jumped more than 8% Monday. Supplies of gas, a key heating and power-generation fuel in Europe, are well below their recent average for the time of year, raising concerns stockpiles will run low as cold weather lifts demand. U.S. natural-gas futures rose 1.9% to $4 per million British thermal units.\nTurkey’s lira slumped 4% to trade at 14.46 to the dollar ahead of an expected rate cut by the central bank on Thursday. The Central Bank of the Republic of Turkey has bowed to pressure from President Recep Tayyip Erdogan to lower borrowing costs this year in the face of rapid inflation, hitting the currency hard.\nOverseas stock markets were mixed. The Stoxx Europe 600 edged up 0.1%, led higher by shares of basic-resources, auto and oil-and-gas companies. Among individual movers,Vifor Pharmajumped more than 15% after the Swiss pharmaceutical firm said it was in talks to be bought by Australia’s CSL.\nJapan’s Nikkei 225 rose 0.7%, the Shanghai Composite Index added 0.4% and Hong Kong’s Hang Seng slipped 0.2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604301439,"gmtCreate":1639325093032,"gmtModify":1639325093141,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/604301439","repostId":"2190719536","repostType":4,"isVote":1,"tweetType":1,"viewCount":1201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605624338,"gmtCreate":1639155725026,"gmtModify":1639155782282,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3565930395680990","authorIdStr":"3565930395680990"},"themes":[],"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605624338","repostId":"1165282830","repostType":4,"repost":{"id":"1165282830","kind":"news","pubTimestamp":1639148461,"share":"https://www.laohunote.com/m/news/1165282830?lang=&edition=full","pubTime":"2021-12-10 23:01","market":"us","language":"en","title":"Tesla stops taking Model S and Model X orders outside North America","url":"https://stock-news.laohu8.com/highlight/detail?id=1165282830","media":"Electrek","summary":"Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outs","content":"<p>Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outside North America.</p>\n<p>It now expects deliveries in other markets to start during the second half of 2022.</p>\n<p>The news comes from an email that Tesla started sending out to people who have Model S and Model X vehicles on order in Europe.</p>\n<p>Tesla writes in the email that it is not accepting any new orders (translated from German):</p>\n<blockquote>\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n</blockquote>\n<p>This is in response to Tesla likely having a large backlog of Model S/X orders in Europe and other markets, where there has been no new Model S/X shipment in a year.</p>\n<p>Tesla shut down Model S and Model X production in January of last year to update the vehicles.</p>\n<p>During that year, the automaker kept taking new orders, but production was delayed with new Model S starting to slowly come off the assembly line in June and&nbsp;Model X in October.</p>\n<p>Tesla is still catching up to the backlog in North America while new orders kept coming in from Europe and Asia.</p>\n<p>In the email, Tesla says that it now aims to deliver the first Model S and Model X in Europe during the second half of next year:</p>\n<blockquote>\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n</blockquote>\n<p>This means that Europe would be without Model S and Model X for a year and a half.</p>\n<p>Here’s the email in full:</p>\n<blockquote>\n Hello [redacted],\n</blockquote>\n<blockquote>\n We are contacting you regarding the timing of your Model X order. As we expand production capacity, the launch dates for markets outside of North America have been postponed. We will inform you of the delivery times through your Tesla account when production begins.\n</blockquote>\n<blockquote>\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n</blockquote>\n<blockquote>\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n</blockquote>\n<blockquote>\n The price of your Model X will continue to be the same as it was when you placed your order, unless your vehicle configuration has been changed. To apply your order fee to another model, or to receive a full refund, request a call to speak directly to a Tesla representative.\n</blockquote>\n<blockquote>\n We apologize for any inconvenience this may cause.\n</blockquote>\n<blockquote>\n Kind regards,\n</blockquote>\n<blockquote>\n Your Tesla Team Testa\n</blockquote>","source":"lsy1627037122897","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stops taking Model S and Model X orders outside North America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stops taking Model S and Model X orders outside North America\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://electrek.co/2021/12/10/tesla-stops-taking-model-s-x-orders-outside-north-america/><strong>Electrek</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outside North America.\nIt now expects deliveries in other markets to start during the second half of ...</p>\n\n<a href=\"https://electrek.co/2021/12/10/tesla-stops-taking-model-s-x-orders-outside-north-america/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://electrek.co/2021/12/10/tesla-stops-taking-model-s-x-orders-outside-north-america/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165282830","content_text":"Tesla announced to potential buyers today that it stopped taking new Model S and Model X orders outside North America.\nIt now expects deliveries in other markets to start during the second half of 2022.\nThe news comes from an email that Tesla started sending out to people who have Model S and Model X vehicles on order in Europe.\nTesla writes in the email that it is not accepting any new orders (translated from German):\n\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n\nThis is in response to Tesla likely having a large backlog of Model S/X orders in Europe and other markets, where there has been no new Model S/X shipment in a year.\nTesla shut down Model S and Model X production in January of last year to update the vehicles.\nDuring that year, the automaker kept taking new orders, but production was delayed with new Model S starting to slowly come off the assembly line in June and Model X in October.\nTesla is still catching up to the backlog in North America while new orders kept coming in from Europe and Asia.\nIn the email, Tesla says that it now aims to deliver the first Model S and Model X in Europe during the second half of next year:\n\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n\nThis means that Europe would be without Model S and Model X for a year and a half.\nHere’s the email in full:\n\n Hello [redacted],\n\n\n We are contacting you regarding the timing of your Model X order. As we expand production capacity, the launch dates for markets outside of North America have been postponed. We will inform you of the delivery times through your Tesla account when production begins.\n\n\n Your Model X is getting closer to delivery. We currently expect shipments outside of North America to begin in the second half of 2022.\n\n\n In order to expedite the delivery of existing orders, including your Model X order, as much as possible, we are currently no longer accepting new orders for the Model S and Model X from markets outside of North America.\n\n\n The price of your Model X will continue to be the same as it was when you placed your order, unless your vehicle configuration has been changed. To apply your order fee to another model, or to receive a full refund, request a call to speak directly to a Tesla representative.\n\n\n We apologize for any inconvenience this may cause.\n\n\n Kind regards,\n\n\n Your Tesla Team Testa","news_type":1},"isVote":1,"tweetType":1,"viewCount":1351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}